GlobeImmune, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for the treatment of cancer. Headquartered in Louisville, Colorado, the company leverages a proprietary platform designed to stimulate T-cell responses against tumor-associated and mutated antigens. GlobeImmune’s approach centers on formulating combinations of heat shock proteins, cytokines and plasmid DNA to elicit durable immune activity in patients with solid tumors.
The company’s lead investigational candidates include GI-4000, a Ras-mutated antigen vaccine being evaluated in pancreatic and colorectal cancer, and GI-6207, which targets carcinoembryonic antigen (CEA) in colorectal and non-small cell lung cancers. A third program, GI-6301, is directed against the survivin protein and has been studied in chordoma and other solid tumor indications. GlobeImmune has completed multiple Phase I and II trials, demonstrating favorable safety and immunogenicity profiles and laying the groundwork for potential late-stage studies or partnering arrangements.
GlobeImmune operates a manufacturing facility in Louisville that supports its clinical supply needs and collaborates with leading academic and medical research institutions across North America and Europe. These partnerships facilitate patient enrollment in multi-center trials and grant the company access to specialized immunomonitoring and translational research capabilities. GlobeImmune’s business strategy emphasizes strategic alliances to advance its pipeline while preserving capital.
Since its inception, the company has pursued a dual path of internal innovation and external collaboration. With a small dedicated team of scientific and clinical experts, GlobeImmune continues to refine its vaccine technology and expand its development footprint in oncology, aiming to address unmet medical needs through precision immunotherapy.
AI Generated. May Contain Errors.
Free GBIM Stock Alerts